Navigation Links
Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™
Date:3/3/2011

tential in treating osteomyelitis and lung infections in cystic fibrosis patients.  This progress requires us to continue to allocate resources to build a very experienced clinical management team so we can continue the progress of these two differentiated antibiotic candidates and maximize their chances for success."

Dr. Oldach will be working closely with Jennifer Schranz, M.D., vice president, clinical affairs, in advancing both programs into pivotal clinical trials.  He joins Cempra from Gilead Sciences, where between 2006 and 2011 he helped lead the early clinical development of the company's hepatitis C (HCV) pipeline. He also supported supplemental New Drug Applications (sNDAs) in the U.S. and Marketing Authorization Applications (MAAs) in the European Union as well as Investigational New Drug Applications (INDs) for seven unique compounds.  Prior to Gilead Sciences, Dr. Oldach was an associate professor of medicine at the University of Maryland School of Medicine, where he also received his medical degree, and served as the Infectious Disease Section Chief in the Baltimore Veterans Administration Hospital.  He has published over 50 peer-reviewed articles and 12 invited editorials and book chapters.  He is an elected fellow of the Infectious Disease Society of America.

Jane Anderson, Ph.D. joins Cempra as director of clinical research and operations following nearly 20 years of experience at several biopharmaceutical companies.  She will be responsible for directing the multiple clinical operations of the company.  She was a key contributor to the ultimate NDA submissions and approvals for two anti-viral agents, while at Gilead.  

Angela Paulovits joins Cempra as a clinical study manager following her tenure as a clinical research associate at ICON Clinical Research.

Sara Wu, Ph.D., is joining Cempra as a senior chemist.  She has over 12 years of experience in pharmaceutical formulation
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
2. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
3. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
4. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
5. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
6. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
7. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
8. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
9. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
10. Cellectar Expands Clinical Management Team
11. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Ill., July 25, 2014 NOT FOR ... OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO ... OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ABBV ... June 30, 2014. "This was another very ... per share above our original guidance and announced plans to ...
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals Holdings ... that will be added to Parnell,s already extensive ... Pty Ltd, a biotechnology company. The compounds now ... shown promise in bone regeneration and dermal regeneration, ... the compounds for the veterinary market with the ...
(Date:7/24/2014)... and MARSEILLE, France , July 24, ... global license from University of Tokyo enables development of ... gene panels, for blood cancers  Mutations of ... favorable prognosis for patients with bone marrow disorders known ... developing companion diagnostics to guide treatment with new anti-cancer ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... SAN DIEGO, Oct. 29 NuVasive, Inc. (Nasdaq: ... products for minimally disruptive surgical treatments for the spine, ... Executive Vice President, will present at the Oppenheimer 20th ... New York, New York, on Tuesday, November 3, 2009. ...
... , This holiday season, settle your stomach, relieve your wallet ... for the holidays, when many of us may suffer from occasional ... Health finds that you probably don,t need an expensive drug ... new report uses comparative effectiveness research to identify "Best Buys" based ...
Cached Medicine Technology:NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference 2NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference 3Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 2Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 3
(Date:7/25/2014)... 25, 2014 SF Cable, internet distributor ... in stock and custom-made, delivered at the lowest prices ... announce the availability of its exclusive line of ... angle cables and adapters provide connectivity in the most ... Male A, Male B, Female and Mini 5pin. , ...
(Date:7/25/2014)... July 25, 2014 (HealthDay News) -- Twins, genes may ... environment, according to a new study. Researchers ... putting words together and grammar, were largely inherited. ... the "twinning effect" (a lower level of language performance ... twins than non-identical twins. "This finding disputes hypotheses ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 The Europe ... solutions market in Europe with analysis and forecast of ... $13.53 billion in 2014 to $19.07 billion by 2019, ... , Browse through the TOC of the Europe Cyber ... in-depth analysis provided. It also provides a glimpse of ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 “You have a ... than 500 people and their loved ones across the U.S. ... a brain tumor diagnosis is typically met with confusion and ... new and difficult vocabulary, and make critical decisions about a ... tumor diagnosis is accompanied by a sense of isolation and ...
(Date:7/25/2014)... The North America Artificial lift market report defines and segments ... forecast of revenue. The artificial lift market in North America ... to around $7 billion by 2018, at a CAGR of ... TOC of North America artificial lift market report, to get ... glimpse of the segmentation in North America Artificial lift market, ...
Breaking Medicine News(10 mins):Health News:SF Cable Presents Exclusive Custom 90° Angle USB Cables and Adaptors 2Health News:Genes May Be Key to Language Delay in Kids 2Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 4Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 2Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 4
... Funnel Cancer Research to ... ... medical practices in Nevada and SW Utah will benefit from a,new ... Institute (NVCI). The new partnership,will provide resources to help local physicians ...
... new study in the Journal of Communication reveals that ... more than simply providing a list of URLs to accredited sites. ... the second leading cause of cancer death among women. Led by ... out to examine what type of access to internet resources would ...
... WORTH, Texas, July 15 Wound Management,Technologies, Inc., ... a new 510K on a new wound management ... new product (patent pending) will combine the hydrolyzed ... and,will initially be available in gel form. Hydrolyzed ...
... an association between certain past diagnostic radiation procedures and ... rare form of prostate cancer which affects about 10 ... , The study, the first of its kind to ... diagnostic procedures and the risk of prostate cancer, was ...
... Provides consistent information and streamlines service delivery to ... ... Lagan, a provider of enterprise,case management solutions that streamline the delivery ... Lagan Human Services(TM) to support the county,s e-Government,initiative for its Human ...
... survival, study finds , , TUESDAY, July 15 (HealthDay News) ... brain tumors called glioblastoma multiforme (GBM) may help boost ... new report says. , An article in the ... this would mark the first time a tumor-altering therapeutic ...
Cached Medicine News:Health News:Physicians Practice and Nevada Cancer Institute Partner to Improve Patient Care 2Health News:Physicians Practice and Nevada Cancer Institute Partner to Improve Patient Care 3Health News:Focused Internet services provide better support to breast cancer patients 2Health News:Wound Management Technologies, Inc. Announces Filing of a 510K 2Health News:Possible link found between X-rays and prostate cancer 2Health News:Hennepin County, Minnesota Selects Lagan Human Services(TM) to Support Human Services and Public Health Department e-Government Initiative 2Health News:Hennepin County, Minnesota Selects Lagan Human Services(TM) to Support Human Services and Public Health Department e-Government Initiative 3Health News:Brain Cancer Vaccine's Immune Response Key to Outcomes 2
Opti-One multi-purpose solution with citrate protein removal and advanced surfactant combination....
Light weight adjustable trial frame, adult...
Classic Trial Frames UB3 that has long set the standard....
Non Sterile surgical blade....
Medicine Products: